A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Study Overview

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).

The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis [Tdap]) and Pneumovax 23 (PPSV) vaccines in adult participants with moderate-to-severe AD treated with amlitelimab versus placebo. The study will evaluate the percentage of participants achieving a positive anti-tetanus response at Week 16 (primary endpoint) and a positive anti-pneumococcal response at Week 16 (primary endpoint).

Study details include:

The study duration will be up to 36 weeks (for participants not entering the LTS17367 [RIVER-AD]).

The screening period will be 2 to 4 weeks. The treatment duration will be up to 16 weeks. The post-treatment safety follow-up period will be16 weeks. The number of visits will be up to 7 (or 6 for those entering LTS17367 [RIVER-AD]).

Study details

The study duration will be up to 36 weeks

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Dermatitis Atopic
  • Age: 18 Years
  • Gender: All

Inclusion Criteria:

  • Participants must be 18 years of age (when signing informed consent form)
  • Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)
  • Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments
  • Validated Investigator Global Assessment scale for atopic dermatitis (vIGA-AD) of 3 or 4 at baseline visit
  • Eczema area and severity index (EASI) score of 12 or higher at baseline
  • AD involvement of 10% or more of body surface area (BSA) at baseline
  • Able and willing to comply with requested study visits and procedures
  • Body weight ≥40 kg and ≤150 kg

Exclusion Criteria:

  • Skin co-morbidity that would adversely affect the ability to undertake AD assessments
  • Receipt of any vaccine (expect influenza and COVID-19 vaccines) within 3 months prior to screening
  • Receipt of any pneumococcal vaccine within approximate timeframe of 5 years prior to screening
  • Prior receipt of two or more doses of Pneumovax 23 at any time
  • Receipt of any tetanus-, diphtheria-, or pertussis-containing vaccine within approximate timeframe of 5 years prior to screening
  • Participants for whom administration of the pneumococcal vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
  • Participants for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this study is contraindicated or medically inadvisable, according to local label of the vaccine
  • Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit
  • Known history of or suspected significant current immunosuppression
  • Any malignancies or history of malignancies prior to baseline (excluding in situ excised and cured cervical carcinoma, non-melanoma skin cancer excised and cured >3 years prior to baseline)
  • History of solid organ or stem cell transplant
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 2 weeks prior baseline
  • Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB
        The above information is not intended to contain all considerations relevant to a potential
        participation in a clinical trial.

Updated on 25 Apr 2024. Study ID: NCT06015308

Find a Study Location to Connect

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site